[go: up one dir, main page]

CR20160261A - Sistema de administración farmacológico - Google Patents

Sistema de administración farmacológico

Info

Publication number
CR20160261A
CR20160261A CR20160261A CR20160261A CR20160261A CR 20160261 A CR20160261 A CR 20160261A CR 20160261 A CR20160261 A CR 20160261A CR 20160261 A CR20160261 A CR 20160261A CR 20160261 A CR20160261 A CR 20160261A
Authority
CR
Costa Rica
Prior art keywords
thermoplastic polymer
therapeutic agent
administration system
pharmacological administration
core
Prior art date
Application number
CR20160261A
Other languages
English (en)
Inventor
Graaff Wouter; De
Willy J H Verhoeven
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of CR20160261A publication Critical patent/CR20160261A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En el presente documento se describe un sistema de administración farmacológico intravaginal que comprende (i) un núcleo que comprende un primer polímero termoplástico y un primer agente terapéutico, en el que el primer agente terapéutico se disuelve en el primer polímero termoplástico , y (ii) una capa externa que rodea el núcleo que comprende un segundo polímero termoplástico, en el que el primer agente terapéutico es menos permeable en el segundo polímero termoplástico que el primer polímero termoplástico, y un segundo agente terapéutico en forma sólida, en el que el segundo agente terapéutico está cargado en una porción de la capa externa.
CR20160261A 2013-12-11 2014-12-08 Sistema de administración farmacológico CR20160261A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361914500P 2013-12-11 2013-12-11
EP13196737 2013-12-11
PCT/EP2014/076823 WO2015086491A1 (en) 2013-12-11 2014-12-08 Drug delivery system.

Publications (1)

Publication Number Publication Date
CR20160261A true CR20160261A (es) 2016-08-16

Family

ID=49759119

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20160261A CR20160261A (es) 2013-12-11 2014-12-08 Sistema de administración farmacológico

Country Status (23)

Country Link
US (1) US10413504B2 (es)
EP (1) EP3079660B1 (es)
JP (1) JP6251396B2 (es)
KR (1) KR101808977B1 (es)
CN (1) CN105979930B (es)
AP (1) AP2016009223A0 (es)
AU (1) AU2014363724B2 (es)
BR (1) BR112016013325B1 (es)
CA (1) CA2931559C (es)
CR (1) CR20160261A (es)
DO (1) DOP2016000132A (es)
EA (1) EA031802B1 (es)
HK (1) HK1224208A1 (es)
IL (1) IL245544A0 (es)
MA (1) MA39059A1 (es)
MD (1) MD20160079A2 (es)
MX (1) MX2016007681A (es)
PE (1) PE20160680A1 (es)
PH (1) PH12016501083A1 (es)
SG (1) SG11201604660VA (es)
SV (1) SV2016005214A (es)
TW (1) TW201607563A (es)
WO (1) WO2015086491A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3079659B1 (en) 2013-12-11 2020-10-28 Merck Sharp & Dohme B.V. Drug delivery system for delivery of anti-virals
US10413504B2 (en) 2013-12-11 2019-09-17 Merck Sharp & Dohme Corp. Intravaginal ring drug delivery system
CN105828793B (zh) 2013-12-19 2019-06-18 宝洁公司 使用糖使角蛋白纤维成形
MX357743B (es) 2013-12-19 2018-07-23 Procter & Gamble Formacion de fibras de queratina con 2-hidroxipropano-1,2,3-acido tricarboxilico y/o 1,2,3,4-acido butanetetracarboxilico.
EP3082733A1 (en) 2013-12-19 2016-10-26 The Procter & Gamble Company Shaping keratin fibres using an active agent comprising a functional group selected from the group consisting of: -c(=o)-, -c(=o)-h, and -c(=o)-o-
EP3082735B1 (en) 2013-12-19 2018-05-02 The Procter and Gamble Company Shaping keratin fibres using oxoethanoic acid and/or derivatives thereof
JP6396473B2 (ja) 2013-12-19 2018-09-26 ザ プロクター アンド ギャンブル カンパニー −ｃ（ｏｈ）−及び−ｃ（＝ｏ）ｏｈから選択される少なくとも２個の官能基を含む活性剤を使用した、ケラチン繊維の成形
EP3082744A1 (en) 2013-12-19 2016-10-26 The Procter & Gamble Company Shaping keratin fibres using carbonate ester
JP2016540006A (ja) 2013-12-19 2016-12-22 ザ プロクター アンド ギャンブル カンパニー 還元性組成物及び定着用組成物を使用したケラチン繊維の整形
EP3017809A1 (en) * 2014-11-07 2016-05-11 Ferring B.V. Drug-device unit containing quinagolide
WO2016100257A1 (en) 2014-12-19 2016-06-23 The Procter & Gamble Company Shaping keratin fibres using arabinose and ethylene carbonate
EP3297730A1 (en) 2014-12-19 2018-03-28 The Procter and Gamble Company Method of shaping keratin fibres
US10945931B2 (en) 2015-06-18 2021-03-16 The Procter And Gamble Company Shaping keratin fibres using dialdehyde compounds
CA2995297C (en) * 2015-08-11 2024-01-02 Ptt Holding Aps A delivery device
EP3395335A1 (en) * 2017-04-24 2018-10-31 Kern Pharma, S.L. Vaginal ring for the simultaneous release of two active ingredients
DE102017113166A1 (de) * 2017-06-14 2018-12-20 Amw Gmbh Depotform zur Abgabe eines Östrogen-Wirkstoffs
AU2019275406B2 (en) 2018-05-24 2024-11-14 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
EP3803866A4 (en) 2018-05-24 2022-03-16 Nureva Inc. METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS
KR20210013089A (ko) 2018-05-24 2021-02-03 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치
US10918649B2 (en) 2019-06-21 2021-02-16 The Population Council, Inc. System for providing birth control
US12472148B2 (en) 2021-04-26 2025-11-18 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
EP4465939A4 (en) * 2022-01-21 2026-01-07 The Population Council Inc Intravaginal Combination Therapy Rings
EP4215180A1 (en) * 2022-01-21 2023-07-26 Sever Pharma Solutions A drug delivery system
AU2023401287A1 (en) 2022-12-02 2025-06-19 Vari Bioscience Gmbh Estriol vaginal ring

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3545439A (en) 1968-01-04 1970-12-08 Upjohn Co Medicated devices and methods
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3995634A (en) 1975-12-02 1976-12-07 The Procter & Gamble Company Vaginal cavity dispensing means and method
US3995633A (en) 1975-12-02 1976-12-07 The Procter & Gamble Company Vaginal Medicament dispensing device
US4237885A (en) 1978-10-23 1980-12-09 Alza Corporation Delivery system with mated members for storing and releasing a plurality of beneficial agents
US4292965A (en) 1978-12-29 1981-10-06 The Population Council, Inc. Intravaginal ring
DE3040978A1 (de) 1980-10-28 1982-05-27 Schering Ag, 1000 Berlin Und 4619 Bergkamen Vaginalring
US4629449A (en) 1982-07-29 1986-12-16 Alza Corporation Vaginal dispenser for dispensing beneficial hormone
EP0162492B1 (en) 1984-04-11 1989-08-02 Thiemann Arzneimittel GmbH Dosage units for controlled release of active material
EP0180264A1 (en) 1984-10-12 1986-05-07 Akzo N.V. Release system for two or more active substances
US4816258A (en) 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
EP0303306B1 (en) 1987-08-08 1993-03-10 Akzo N.V. Contraceptive implant
AU3432689A (en) 1988-03-24 1989-10-16 Bukh Meditec A/S Controlled release composition
US5766632A (en) 1993-10-01 1998-06-16 Legere Pharmaceuticals, Ltd. Method of using lectins for contraception
JP3720386B2 (ja) 1993-12-27 2005-11-24 住友製薬株式会社 薬物放出制御製剤
DE69616551T2 (de) 1995-07-04 2002-05-29 Akzo Nobel N.V., Arnheim/Arnhem Ringförmige vorrichtung
US5972372A (en) 1996-07-31 1999-10-26 The Population Council, Inc. Intravaginal rings with insertable drug-containing core
FR2754179B1 (fr) 1996-10-08 1998-12-24 Theramex Nouvelle composition hormononale et son utilisation
IL123813A0 (en) * 1997-04-11 1998-10-30 Akzo Nobel Nv Drug delivery system for two or more active substances
ATE246638T1 (de) 1997-12-12 2003-08-15 Akzo Nobel Nv Verpackung für einen vaginalring
ID25660A (id) 1997-12-18 2000-10-19 Lilly Co Eli Teripatide kristal
US6579533B1 (en) 1999-11-30 2003-06-17 Bioasborbable Concepts, Ltd. Bioabsorbable drug delivery system for local treatment and prevention of infections
IL157771A0 (en) 2001-03-27 2004-03-28 Galen Chemicals Ltd Intravaginal drug delivery devices for the administration of an antimicrobial agent
WO2003000156A1 (en) 2001-06-22 2003-01-03 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
CN1289064C (zh) 2001-08-31 2006-12-13 先灵有限责任公司 药物输送体系
NZ532097A (en) 2001-09-28 2006-02-24 Mcneil Ppc Inc Dosage forms having an inner core and outer shell
CN1242819C (zh) 2002-06-07 2006-02-22 上海市计划生育科学研究所 一种新型阴道环及制备方法
US6992219B2 (en) 2002-08-09 2006-01-31 Cephalon France Modafinil polymorphic forms
TWI336627B (en) * 2003-05-23 2011-02-01 Organon Nv Drug delivery system,and use and manufacturing method thereof
US20070043332A1 (en) 2003-07-10 2007-02-22 Galen (Chemiclas) Liimited Intravaginal drug delivery devices
AU2004275469B2 (en) * 2003-09-29 2010-07-15 Novo Nordisk Health Care Ag HRT formulations
US8481079B2 (en) * 2004-03-24 2013-07-09 Merck Sharp & Dohme B.V. Drug delivery system based on polyethylene vinylacetate copolymers
KR20060046263A (ko) * 2004-08-04 2006-05-17 도쿄파츠고교 가부시키가이샤 편평형 진동모터를 내장시킨 전자음향변환기
TW200727920A (en) 2005-06-21 2007-08-01 Organon Nv New regimens for oral monophasic contraceptives
CA2669066A1 (en) * 2006-11-20 2008-05-29 N.V. Organon Helically-shaped drug delivery system
WO2008100876A1 (en) 2007-02-12 2008-08-21 Particle Sciences, Inc. Delivery devices containing encapsulated and/or particle-bound active pharmaceutical ingredients
AR065816A1 (es) 2007-03-26 2009-07-01 Theramex Regimen anticonceptivo oral
NZ598483A (en) 2007-09-07 2013-08-30 Quadra Logic Tech Inc Drug cores for sustained release of therapeutic agents
TW200930343A (en) * 2007-09-21 2009-07-16 Organon Nv Drug delivery system
TW200927141A (en) 2007-11-22 2009-07-01 Bayer Schering Pharma Oy Vaginal delivery system
US8753667B2 (en) 2009-07-21 2014-06-17 The Population Council, Inc. Multi-layered gradient vaginal ring
EP2468750A1 (en) 2010-12-13 2012-06-27 Chemo Ibérica, S.A. Polymorphic forms of asenapine maleate and processes for their preparation
TW201332585A (zh) 2012-02-14 2013-08-16 Chemo Res S L 核鞘藥物遞送裝置
US10413504B2 (en) 2013-12-11 2019-09-17 Merck Sharp & Dohme Corp. Intravaginal ring drug delivery system

Also Published As

Publication number Publication date
BR112016013325B1 (pt) 2022-11-29
WO2015086491A1 (en) 2015-06-18
US20150157561A1 (en) 2015-06-11
KR20160095110A (ko) 2016-08-10
HK1224208A1 (zh) 2017-08-18
MX2016007681A (es) 2016-10-14
PE20160680A1 (es) 2016-07-31
EP3079660B1 (en) 2021-03-03
KR101808977B1 (ko) 2017-12-13
MD20160079A2 (ro) 2016-10-31
EP3079660A1 (en) 2016-10-19
EA201691193A1 (ru) 2016-09-30
CN105979930B (zh) 2019-11-19
EA031802B1 (ru) 2019-02-28
DOP2016000132A (es) 2016-07-31
SG11201604660VA (en) 2016-07-28
AU2014363724A1 (en) 2016-05-26
SV2016005214A (es) 2016-11-21
US10413504B2 (en) 2019-09-17
CN105979930A (zh) 2016-09-28
TW201607563A (zh) 2016-03-01
AU2014363724B2 (en) 2017-02-23
JP6251396B2 (ja) 2017-12-20
JP2016539991A (ja) 2016-12-22
CA2931559A1 (en) 2015-06-18
MA39059A1 (fr) 2018-08-31
PH12016501083A1 (en) 2016-07-25
CA2931559C (en) 2018-03-13
AP2016009223A0 (en) 2016-05-31
IL245544A0 (en) 2016-06-30
BR112016013325A2 (es) 2017-08-08

Similar Documents

Publication Publication Date Title
DOP2016000132A (es) Sistema de administración farmacologico
MX2015012367A (es) Dispositivos de suministro de farmacos con un componente permeable al farmaco y metodos.
CR11630A (es) Sistema de administracion de drogas con efecto estabilizante
CR20140487A (es) Peliculas de capas multiples capaces de liberar ingredientes activos por un periodo limitado de tiempo
PE20150129A1 (es) Formulacion de farmaco de liberacion retardada
AR081113A1 (es) Liberacion pulsatil de medicamentos desde un tapon de punctum
ECSP10010079A (es) Sistema para el suministro de una droga
AR062321A1 (es) Sistema de liberacion controlada y metodo para fabricarlo
MX2018014906A (es) Composiciones farmaceuticas nasales con un excipiente poroso.
BR112016012615A8 (pt) sistemas, e kit
MX2020000651A (es) Sistema de administracion transdermica con una membrana microporosa que tiene poros llenos de solvente.
ES2527276T3 (es) Balón con superficie recubierta
MX2018001499A (es) Sistema para la entrega de polimeros liquidos para la administracion prolongada de farmacos.
CL2015001882A1 (es) Sistema de entrega de fragancias
AR061860A1 (es) Prepracion farmaceutica para la administracion oral con liberacion controlada de ingrediente activo en el intestino delgado y metodo para su fabricacion
MX2020003665A (es) Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende por lo menos un aditivo.
MX2015008525A (es) Material polimerico celular.
AR089765A1 (es) Un sistema para el suministro de un farmaco
CL2016000944A1 (es) Nueva formulación de ganadotropinas
MX2019004938A (es) Cápsula compleja que contiene esomeprazol y método de preparación de esta.
AR099135A1 (es) Administración retardada de sustancias químicas en un pozo
CL2015002560A1 (es) Un método para tratar infecciones, enfermedades o desordenes de la unidad ungueal, con un dispositivo para implantar una composición en una ubicación determinada y un régimen de dosificación para tratar una enfermedad o trastorno de la unidad ungueal.
NI201600077A (es) Sistema de administración farmacológico
CO2018002590A2 (es) Sistemas y métodos para utilizar estructuras biomiméticas que proporcionan comunicación en tejidos vivientes
CU20160026A7 (es) Formulación de fármaco de liberación retardada